Germany's Nordex prelim Q3 sales slightly beat estimates; raises 2026 margin outlook

By Reuters News


Overview

  • German wind turbine maker's preliminary Q3 sales rose yr/yr and slightly beat analyst expectations

  • Preliminary Q3 EBITDA margin improved to 12.7%, driven by higher Service margins and strong project execution

  • Company raised full-yr EBITDA margin guidance to 11.5%-12.5%


Outlook

  • Nordex raises 2026 EBITDA margin guidance to 11.5%-12.5% from 8.0%-11.0%

  • Company maintains all other elements of its full-year 2026 guidance

  • Company says improved outlook is due to higher Service margins and strong project execution


Result Drivers

  • SERVICE SEGMENT MARGINS - Co said higher margins in Service segment drove Q3 results and improved outlook

  • PROJECT EXECUTION - Co attributed better-than-expected Q3 results to strong project execution

  • PROJECT RISKS - Co said risks assumed in the Projects segment did not materialize to the extent previously anticipated


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

Slight Beat*

EUR 2.19 bln

EUR 2.17 bln (6 Analysts)

Q3 EBITDA

EUR 278 mln

Q3 EBITDA Margin

12.70%

Q3 Free Cash Flow

EUR 379 mln

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the heavy electrical equipment peer group is "buy"

  • Wall Street's median 12-month price target for Nordex SE is €50.00, about 43.4% above its October 15 closing price of €34.86

  • The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 21 three months ago


Reuters Recommended Reads

  • Oct 13 - Europe's mass-market carmakers under 'enormous pressure', Volkswagen CEO says

  • Oct 13 - European automakers urge support as VW warns of 'enormous pressure'

  • Oct 13 - BioNTech's mRNA cancer therapy misses first goal in head and neck trial


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.